B+
Bull case
25%
Probability
Target price
$31.46
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
ELAN
Elanco Animal HealthANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$25.99
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+80.7
Score
AI commentary
News tone is positive following the Q2 beat and raised outlook. Stored earnings context described a positive market reception but reported ELAN at $22.75 versus $25.60 before earnings; the RankAlpha anchor later recovered to $24.42 on August 24. Analyst revisions and target changes are unavailable, so confidence remains constructive rather than aggressive. Direct animal-health references provide better context than broad biopharma peers, but they are not perfectly comparable.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-05eventQ2 beat and raised FY2026 outlookMedium impact
Elanco reported Q2 revenue of $1.368 billion, 8% organic constant-currency growth, adjusted EBITDA of $288 million, and raised full-year revenue, EBITDA, EPS, innovation-revenue, and leverage targets. [#SEC-8K-2026-08-05]
2026-12-31catalystInnovation portfolio commercializationHigh impact
Zenrelia reached blockbuster status and approximately 18,000 U.S. clinics; Credelio Quattro exceeded 50% U.S. clinic penetration. H2 execution depends on continued share gains, clinic penetration, and Befrena capacity expansion. [#SEC-8K-2026-08-05]
2026-12-31catalystMargin expansion and deleveragingHigh impact
Q2 adjusted EBITDA margin was 21.2%; full-year guidance implies approximately 13% midpoint EBITDA growth and a year-end net leverage target near 3.0x adjusted EBITDA. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology